Inactive

The Centers for Disease Control and Prevention (CDC), National Center for Immunization ans Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), hereby announces its intent to issue an a... The Centers for Disease Control and Prevention (CDC), National Center for Immunization ans Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), hereby announces its intent to issue an award a sole source, firm fixed-price purchase order to Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122-4616, for the purchase of MiSeq Reagent Kit v2 and the Nextera XT DNA Library Preparation Kit. Illumina, Inc., is the only source that can provide the MiSeq Reagent Kit v2 and the Nextera XT DNA Library Preparation Kit deemed necessary by the CDC needed to detect Legionella isolates. The reagents procured from Illumina will be used in Illumina MiSeq instruments in the lab using the Illumina MiSeq platform. The reagents are unique to Illumina and will be used in conjunction with Illumina MiSequencer. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 13.106-1(b) Simplified Acquisition Procedures only one responsible source and no other supplies or services will satisfy the agency requirement. The sole source procurement will be awarded as a simplified acquisition in accordance with FAR Part 12 and FAR Subpart 13 procedures. The NAICS code for this request is 325413, In-Vitro Diagnostic Substance Manufacturing. THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS; however, all responses received within 15 days of the issuance of this notice will be reviewed by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. Any response must be emailed to the contract specialist Felipe Cardenas at tpp5@cdc.gov by August 22, 2024. No phone calls will be accepted.